FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Ahead of its scheduled opening later this year, the massive Fujifilm Diosynth Biotechnologies manufacturing plant in Holly ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

With combined investments exceeding $53 billion, both companies are deepening their US presence through expanded biologics ...

has signed a $3 billion agreement to make treatments for Regeneron Pharmaceuticals. Under the agreement, announced Tuesday, FujiFilm Diosynth would produce Regeneron’s biologic medicines over 10 ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicineHOLLY SPRINGS, N.C., April 23, 2025 -- ...